Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- IMRX
- Price
- 5.12
- Stock movement up
- +0.19 (3.85%)
- Company name
- Immuneering Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 330.60M
- Ent value
- 116.11M
- Price/Sales
- 455.17
- Price/Book
- 1.45
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 175.27%
- 3 year return (CAGR)
- 10.35%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 455.17 |
| Price to Book | 1.45 |
| EV to Sales | 159.87 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 64.57M |
| EPS (TTM) | -1.58 |
| FCF per share (TTM) | -1.26 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 726.33K |
| Gross profit (TTM) | -528.41K |
| Operating income (TTM) | -64.18M |
| Net income (TTM) | -62.50M |
| EPS (TTM) | -1.58 |
| EPS (1y forward) | -1.46 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -72.75% |
| Operating margin (TTM) | -8836.45% |
| Profit margin (TTM) | -8604.45% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 227.56M |
| Net receivables | 0.00 |
| Total current assets | 229.10M |
| Goodwill | 6.69M |
| Intangible assets | 328.46K |
| Property, plant and equipment | 5.63M |
| Total assets | 241.06M |
| Accounts payable | 1.60M |
| Short/Current long term debt | 3.92M |
| Total current liabilities | 9.55M |
| Total liabilities | 13.08M |
| Shareholder's equity | 227.98M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -50.01M |
| Capital expenditures (TTM) | 27.67K |
| Free cash flow (TTM) | -50.04M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -27.41% |
| Return on Assets | -25.93% |
| Return on Invested Capital | -27.37% |
| Cash Return on Invested Capital | -21.91% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.88 |
| Daily high | 5.18 |
| Daily low | 4.85 |
| Daily Volume | 578K |
| All-time high | 32.84 |
| 1y analyst estimate | 17.17 |
| Beta | 0.46 |
| EPS (TTM) | -1.58 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 Mar 2026 |
Downside potential
Loading...
Downside potential data
| IMRX | S&P500 | |
| Current price drop from All-time high | -84.41% | -1.82% |
| Highest price drop | -96.86% | -56.47% |
| Date of highest drop | 16 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -77.05% | -10.84% |
| Avg time to new high | 114 days | 12 days |
| Max time to new high | 1102 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
330.60M
Marketcap category
Small-cap
Description
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Employees
54
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page